Matches in SemOpenAlex for { <https://semopenalex.org/work/W1992780020> ?p ?o ?g. }
- W1992780020 endingPage "521" @default.
- W1992780020 startingPage "514" @default.
- W1992780020 abstract "BackgroundIndolent systemic mastocytosis is a group of rare diseases for which reliable predictors of progression and outcome are still lacking.ObjectiveHere we investigate the prognostic impact of the clinical, biological, phenotypic, histopathological, and molecular disease characteristics in adults with indolent systemic mastocytosis, who were followed using conservative therapy.MethodsA total of 145 consecutive patients were prospectively followed between January 1983 and July 2008; in addition, from 1967 to 1983, 20 patients were retrospectively studied.ResultsMultivariate analysis showed that serum β2-microglobulin (P = .003) together with the presence of mast/stem cell growth factor receptor gene (KIT) mutation in mast cells plus myeloid and lymphoid hematopoietic lineages (P = .02) was the best combination of independent parameters for predicting disease progression (cumulative probability of disease progression of 1.7% ± 1.2% at 5-10 years and of 8.4% ± 5.0% at 20-25 years). Regarding overall survival, the best predictive model included age >60 years (P = .005) and development of an associated clonal hematological non–mast cell disorder (P = .03) with a cumulative probability of death of 2.2% ± 1.3% at 5 years and of 11% ± 5.9% at 25 years.ConclusionsIndolent systemic mastocytosis in adults has a low disease progression rate, and the great majority of patients have a normal life expectancy, with the presence of KIT mutation in all hematopoietic lineages and increased serum β2-microglobulin the most powerful independent parameters for predicting transformation into a more aggressive form of the disease. Indolent systemic mastocytosis is a group of rare diseases for which reliable predictors of progression and outcome are still lacking. Here we investigate the prognostic impact of the clinical, biological, phenotypic, histopathological, and molecular disease characteristics in adults with indolent systemic mastocytosis, who were followed using conservative therapy. A total of 145 consecutive patients were prospectively followed between January 1983 and July 2008; in addition, from 1967 to 1983, 20 patients were retrospectively studied. Multivariate analysis showed that serum β2-microglobulin (P = .003) together with the presence of mast/stem cell growth factor receptor gene (KIT) mutation in mast cells plus myeloid and lymphoid hematopoietic lineages (P = .02) was the best combination of independent parameters for predicting disease progression (cumulative probability of disease progression of 1.7% ± 1.2% at 5-10 years and of 8.4% ± 5.0% at 20-25 years). Regarding overall survival, the best predictive model included age >60 years (P = .005) and development of an associated clonal hematological non–mast cell disorder (P = .03) with a cumulative probability of death of 2.2% ± 1.3% at 5 years and of 11% ± 5.9% at 25 years. Indolent systemic mastocytosis in adults has a low disease progression rate, and the great majority of patients have a normal life expectancy, with the presence of KIT mutation in all hematopoietic lineages and increased serum β2-microglobulin the most powerful independent parameters for predicting transformation into a more aggressive form of the disease." @default.
- W1992780020 created "2016-06-24" @default.
- W1992780020 creator A5003161551 @default.
- W1992780020 creator A5011977184 @default.
- W1992780020 creator A5030136239 @default.
- W1992780020 creator A5037604454 @default.
- W1992780020 creator A5045245370 @default.
- W1992780020 creator A5051937379 @default.
- W1992780020 creator A5052953804 @default.
- W1992780020 creator A5060849622 @default.
- W1992780020 creator A5060993448 @default.
- W1992780020 creator A5076091594 @default.
- W1992780020 creator A5086153083 @default.
- W1992780020 date "2009-09-01" @default.
- W1992780020 modified "2023-10-18" @default.
- W1992780020 title "Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients" @default.
- W1992780020 cites W1682346499 @default.
- W1992780020 cites W171982086 @default.
- W1992780020 cites W1970843842 @default.
- W1992780020 cites W1972144397 @default.
- W1992780020 cites W1974100080 @default.
- W1992780020 cites W1975240950 @default.
- W1992780020 cites W1981135441 @default.
- W1992780020 cites W1982418077 @default.
- W1992780020 cites W1987946408 @default.
- W1992780020 cites W1995744217 @default.
- W1992780020 cites W1995840402 @default.
- W1992780020 cites W1999757233 @default.
- W1992780020 cites W2018012923 @default.
- W1992780020 cites W2020368949 @default.
- W1992780020 cites W2020607609 @default.
- W1992780020 cites W2022236617 @default.
- W1992780020 cites W2024510824 @default.
- W1992780020 cites W2031012387 @default.
- W1992780020 cites W2038961612 @default.
- W1992780020 cites W2044457674 @default.
- W1992780020 cites W2048993739 @default.
- W1992780020 cites W2052337657 @default.
- W1992780020 cites W2058481481 @default.
- W1992780020 cites W2060197923 @default.
- W1992780020 cites W2064244980 @default.
- W1992780020 cites W2078329340 @default.
- W1992780020 cites W2087935715 @default.
- W1992780020 cites W2107058988 @default.
- W1992780020 cites W2107789045 @default.
- W1992780020 cites W2109331088 @default.
- W1992780020 cites W2111935453 @default.
- W1992780020 cites W2115823813 @default.
- W1992780020 cites W2122605148 @default.
- W1992780020 cites W2143438679 @default.
- W1992780020 cites W2156160133 @default.
- W1992780020 cites W2158121135 @default.
- W1992780020 cites W2164842318 @default.
- W1992780020 cites W4252888197 @default.
- W1992780020 doi "https://doi.org/10.1016/j.jaci.2009.05.003" @default.
- W1992780020 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19541349" @default.
- W1992780020 hasPublicationYear "2009" @default.
- W1992780020 type Work @default.
- W1992780020 sameAs 1992780020 @default.
- W1992780020 citedByCount "241" @default.
- W1992780020 countsByYear W19927800202012 @default.
- W1992780020 countsByYear W19927800202013 @default.
- W1992780020 countsByYear W19927800202014 @default.
- W1992780020 countsByYear W19927800202015 @default.
- W1992780020 countsByYear W19927800202016 @default.
- W1992780020 countsByYear W19927800202017 @default.
- W1992780020 countsByYear W19927800202018 @default.
- W1992780020 countsByYear W19927800202019 @default.
- W1992780020 countsByYear W19927800202020 @default.
- W1992780020 countsByYear W19927800202021 @default.
- W1992780020 countsByYear W19927800202022 @default.
- W1992780020 countsByYear W19927800202023 @default.
- W1992780020 crossrefType "journal-article" @default.
- W1992780020 hasAuthorship W1992780020A5003161551 @default.
- W1992780020 hasAuthorship W1992780020A5011977184 @default.
- W1992780020 hasAuthorship W1992780020A5030136239 @default.
- W1992780020 hasAuthorship W1992780020A5037604454 @default.
- W1992780020 hasAuthorship W1992780020A5045245370 @default.
- W1992780020 hasAuthorship W1992780020A5051937379 @default.
- W1992780020 hasAuthorship W1992780020A5052953804 @default.
- W1992780020 hasAuthorship W1992780020A5060849622 @default.
- W1992780020 hasAuthorship W1992780020A5060993448 @default.
- W1992780020 hasAuthorship W1992780020A5076091594 @default.
- W1992780020 hasAuthorship W1992780020A5086153083 @default.
- W1992780020 hasBestOaLocation W19927800201 @default.
- W1992780020 hasConcept C10515644 @default.
- W1992780020 hasConcept C109159458 @default.
- W1992780020 hasConcept C126322002 @default.
- W1992780020 hasConcept C143998085 @default.
- W1992780020 hasConcept C2022786 @default.
- W1992780020 hasConcept C203014093 @default.
- W1992780020 hasConcept C21957315 @default.
- W1992780020 hasConcept C2779134260 @default.
- W1992780020 hasConcept C2779282312 @default.
- W1992780020 hasConcept C2780581156 @default.
- W1992780020 hasConcept C28328180 @default.
- W1992780020 hasConcept C54355233 @default.
- W1992780020 hasConcept C71924100 @default.